Effect of mirazid 'commiphora molmol' in treatment of experimental goat fascioliasis

الملخص EN

A controlled test of the efficacy of myriad against all stages immature and mature of fascicle gigantic a have performed in experimentally infected goats.

Goats were orally infected with 100 viable metacercaria and treated post infection (pi) at 6 and 16 weeks with 10mg / kg / daily mirazid for 6 days.

The efficacy of mirazid in treatment of both immature and mature flukes was 86.46 % and 96.64 % respectively.

The influence of myriad treatment on the pathos-physiology of fasciolosis infected goats was also examined.

Anemia was associated with the presence of immature and mature flukes in bile ducts.

Treatment with mirazid largely induced hematological alterations as seen by reduced serum levels of the enzymes aspartate aminotransferase (ast), alanine aminotransferase (alt) and gamma-glutathione transferase (ggt) levels associated with hepatic damage due to fasciolosis.

Early treatment, 6 weeks pi, prevented the development of both parenchyma and bile ducts lesions.

While, treatment at 16 weeks pi had no appreciable effect on the development of hepatic lesions.

Enzyme-linked immunosorbent assay antibody response to f.

gigantica excretory secretory product (esp) was also affected by treatment with mirazid.

In all treated goats, a peak in antibody levels was observed between weeks 12 and 14.

The drug can be regarded as highly effective therapy against mature and immature flukes of goats but more investigations still needed to detect the effect of mirazid on immature stages of flukes in other animals.